title: The role of proteomics in depression research.
abstract: Depression is a severe neuropsychiatric disorder affecting approximately 10% of the world population. Despite this, the molecular mechanisms underlying the disorder are still not understood. Novel technologies such as proteomic-based platforms are beginning to offer new insights into this devastating illness, beyond those provided by the standard targeted methodologies. Here, we will show the potential of proteome analyses as a tool to elucidate the pathophysiological mechanisms of depression as well as the discovery of potential diagnostic, therapeutic and disease course biomarkers.
authors.affiliation: Max Planck Institute for Psychiatry, Kraepelinstr. 2, 80804, Munich, Germany.
authors.forename: Daniel
authors.initials: D
authors.lastname: Martins-de-Souza
authors.forename: Laura W
authors.initials: LW
authors.lastname: Harris
authors.forename: Paul C
authors.initials: PC
authors.lastname: Guest
authors.forename: Christoph W
authors.initials: CW
authors.lastname: Turck
authors.forename: Sabine
authors.initials: S
authors.lastname: Bahn
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology; D015415:Biomarkers; D015283:Citalopram / Q000494:pharmacology; D003866:Depressive Disorder / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D004351:Drug Resistance; D006801:Humans; D051379:Mice; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D020543:Proteome / Q000032:analysis / Q000235:genetics / Q000502:physiology; D040901:Proteomics / Q000379:methods*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology
chemical_list: D000928:Antidepressive Agents; D015415:Biomarkers; D015283:Citalopram; D020543:Proteome; D017367:Selective Serotonin Reuptake Inhibitors